CABRI

CABRI is a global biomedical research company in Ann Arbor, Michigan.

Since our beginnings in 2005, we have been dedicated to helping those poorly served by the for-profit medical and pharmaceutical establishment.

05/28/2026

👉 CABRI funds research at the exact stage where most ideas die.

That is what sets us apart. Most organizations focus on what's already validated, while Cabri invests in what isn't.

There are ideas out there that could change lives, but without support early on, they often never get the chance. Cabri focuses on that stage to help ensure those ideas do not disappear before they can become something more. Because every breakthrough starts with someone giving it a chance.

Every donation helps give those ideas a real chance to become something more. Be part of what starts it → cabrimed.org/donate

05/26/2026

A major shift is happening in rare disease drug development.

The FDA is introducing a new approval pathway that allows therapies to move forward without large clinical trials, using smaller, highly targeted studies instead.

For many rare conditions, large trials have never been realistic. This change opens the door for more therapies to reach patients faster.

At CABRI, this is where our work matters most. We help teams navigate complex development paths with smarter trial design, efficient data strategies, and a focus on what is actually achievable.

As the process evolves, precision becomes everything.

Learn what this means for the future of rare disease therapies ➡️ https://www.healio.com/news/rheumatology/20260223/fda-provides-new-approval-process-for-rare-disease-therapies-without-large-clinical-trials

05/22/2026

Most people do not realize how medical breakthroughs actually happen. CABRI collaborates with leading institutions like University of Michigan, Karolinska Institutet, Technische Universität Dresden, and Cayman Chemical to support early-stage research and advance discoveries in rare diseases and underserved areas of medicine.

These partnerships bring together funding, expertise, and research infrastructure.

That means:
👉 More opportunities to study complex conditions
👉 More data to support discoveries
👉 A stronger path toward potential treatments

This is how progress actually moves forward, and in rare disease research, it wouldn't happen without collaboration.

More people should understand this. Share if you believe collaboration drives real progress.

Learn more about our mission at cabrimed.org.

05/19/2026

The biggest misconception in drug development is that if the science works, the treatment will follow.

In reality, there are over 10,000 rare diseases, yet less than 5% have an approved treatment. More than 300 million people are affected worldwide, but funding and research remain limited. As a result, promising therapies stall, studies never get off the ground, and potential breakthroughs never reach patients, not because the science failed, but because the system did.

CABRI exists to help change that by funding research, supporting early-stage development, and working to move critical discoveries forward in areas that are often overlooked. Because progress is not just about discovery. It's about making sure it actually goes somewhere.

05/14/2026

What does it take to bring a drug to market for just ~150 patients?

The FDA’s accelerated approval of elamipretide for Barth syndrome is a major step forward in ultra-rare disease treatment. But it also highlights a bigger reality: When patient populations are this small, traditional clinical pathways do not always work.

Trials require flexibility. Data sets are limited.

This is why development in ultra-rare disease demands precision at every step. CABRI supports this kind of work, helping teams navigate complex pathways where getting it right matters more than scale.

Learn more → https://www.labiotech.eu/trends-news/elamipretide-fda-approval-ultra-rare-disease/

05/11/2026

Someone you know could be affected by a rare disease. A friend. A sibling. A child.

For many of these conditions, the challenge isn't just the disease itself. It is the lack of funding to study it.

CABRI was built around a gap that still exists in healthcare today.

Limited funding can delay research, reduce opportunities for studies, and prevent promising therapies from moving forward.

Most diseases get funding. Rare ones have to fight for it.

That's exactly what CABRI is here to change.

When you donate, you're not just funding research.

Support that progress 👉 cabrimed.org/donate

05/07/2026

April showers bring May flowers.

It's easy to focus on the outcome. The breakthrough, the treatment, the result. But all of it starts much earlier with funding, early studies, and the data that makes progress possible

Here's what that looks like in research.

Early funding → supports initial studies
Initial studies → generate critical data
Data → enables larger trials and development

The challenge is that many ideas never make it past the first step. Not because they are not promising, but because they are not supported at the start. CABRI is intentional about focusing on that stage so more discoveries have the chance to move forward.

Because breakthroughs depend on what gets funded first.

Explore what we're working on → cabrimed.org

05/05/2026

May is National Cancer Research Month, a time to recognize the researchers, clinicians, and advocates working every day to improve outcomes for patients and families.

It’s also a reminder that cancer research depends on continued funding. Not all cancers receive the same level of attention, and rare cancers like sinonasal undifferentiated carcinoma (SNUC) are often left with fewer resources and fewer research opportunities.

At CABRI, we support research for rare illnesses and orphan diseases because progress starts with giving scientists the funding they need to keep going. Each study adds to what we know and helps build toward better options for people facing rare diagnoses.

This month, we honor the people doing the work and raise awareness for the research that still needs support.

04/30/2026

What an organization chooses not to fund is often more telling than what it does.

In many research settings, indirect costs such as institutional overhead and administrative support can account for a significant share of funding. In NIH-funded research, these costs average around 42% of direct research expenses, with some negotiated rates reaching 50 to 70%. (National Institutes of Health)

At CABRI, we take a different approach. We do not fund indirect or overhead expenses.

This decision is intentional. It ensures that funding is directed toward the work itself, supporting the experiments, data collection, and clinical efforts that move research forward.

04/28/2026

In the United States, a disease is classified as “rare” if it affects fewer than 200,000 people.

That may sound like a small number, but there are more than 7,000 identified rare diseases. When combined, rare diseases affect about 1 in 10 Americans.

Rare doesn’t mean uncommon. It often means underfunded and under-researched.

That’s why CABRI supports research focused on rare and orphan conditions that need dedicated scientific attention.

Learn about our efforts at cabrimed.org

Address

1180 East Ellsworth Road
Ann Arbor, MI
48108

Telephone

+18772029028

Website

http://www.cabrimed.org/

Alerts

Be the first to know and let us send you an email when CABRI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to CABRI:

Shortcuts

Want your organization to be the top-listed Non Profit Organization in Ann Arbor?